10x Genomics Inc.

21 hours ago · gurufocus.com

On September 21, 2026, 10x Genomics Inc (TXG) shares rose 3.3% to a current price of $79.10. The stock has seen a remarkable performance over the past year, wit

12 days ago · prnewswire.com

10x Genomics, a leader in single-cell and spatial biology, to combine its spatial biology technologies with Lunit's AI-powered H&E pathology analysis to advance oncology biomarker discovery SEOUL, South Korea, Sept. 10, 2026 /PRNewswire/ -- Lunit (KRX: 328130), a leading provider of AI for cancer diagnostics and precision oncology, today announced that 10x Genomics, Inc. (Nasdaq: TXG) will incorporate Lunit's AI-powered pathology platform, Lunit SCOPE IO, into its oncology biomarker discovery workflow.

14 days ago · gurufocus.com

On September 08, 2026, 10x Genomics Inc (TXG) shares rose 4.7% today, bringing the current price to $65.61. The stock has seen significant volatility over the p

19 days ago · zacks.com

TXG's 84% rally is backed by consumables growth, Atera demand and higher guidance, but weak instruments and valuation raise the bar.

22 days ago · zacks.com

10x Genomics wins a $4.8M patent verdict against Parse, strengthening its IP position as it seeks added damages and a U.S. injunction.

1 month ago · seekingalpha.com

Atera could meaningfully boost instrument sales in late 2026 and drive recurring high-margin consumables revenue from 2027 onward. TXG's valuation already prices in significant Atera success, but the risk/reward remains skewed to the upside with favorable chart dynamics. Key risks include Atera manufacturing constraints, potential cannibalization of Xenium, rising competition, and ongoing share dilution.

2 months ago · zacks.com

TXG beats Q2 earnings and revenue estimates, expands gross margin and raises its 2026 revenue outlook despite a year-over-year sales decline.

2 months ago · marketbeat.com

10x Genomics NASDAQ: TXG reported second-quarter revenue of $151 million, including $1.6 million in license and royalty revenue tied to its settlement with Takara. Excluding non-recurring settlement revenue in both periods, revenue was $149.4 million, up 3% from a year earlier.

2 months ago · seekingalpha.com

10x Genomics, Inc. (TXG) Q2 2026 Earnings Call Transcript

2 months ago · zacks.com

Although the revenue and EPS for 10x Genomics (TXG) give a sense of how its business performed in the quarter ended June 2026, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.